

# Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research

Rianne Verbeek,<sup>1</sup> Linos Vandekerckhove,<sup>1</sup> Jolien Van Cleemput<sup>1</sup>

**AUTHOR AFFILIATION** See affiliation list on p. 13.

**ABSTRACT** Human herpesvirus 7 (HHV-7) is a common virus that is associated with various human diseases including febrile syndromes, dermatological lesions, neurological defects, and transplant complications. Still, HHV-7 remains one of the least studied members of all human betaherpesviruses. In addition, HHV-7-related research is mostly confined to case reports, while *in vitro* or *in vivo* studies unraveling basic virology, transmission mechanisms, and viral pathogenesis are sparse. Here, we discuss HHV-7-related literature linking clinical syndromes to the viral life cycle, epidemiology, and viral immunopathogenesis. Based on our review, we propose a hypothetical model of HHV-7 pathogenesis inside its host. Furthermore, we identify important knowledge gaps and recommendations for future research to better understand HHV-7 diseases and improve therapeutic interventions.

**KEYWORDS** HHV-7, viral pathogenesis, knowledge gaps, human herpesviruses

Human herpesvirus 7 (HHV-7) is a ubiquitous CD4<sup>+</sup> T-lymphotropic virus that was first isolated from peripheral blood lymphocytes of a healthy individual in 1990 (1). As a member of the *Herpesviridae* family, *Betaherpesvirinae* subfamily, the DNA virus HHV-7 closely resembles human cytomegalovirus (HCMV or HHV-5) and even more so human herpesviruses 6A and 6B (HHV-6A and HHV-6B), here collectively referred to as “HHV-6” unless otherwise specified, with whom it shares the genus *Roseolovirus*. Along with the latter, primary HHV-7 infection is associated with childhood febrile syndromes, whether or not accompanied by a rash, classified as “the sixth disease” (2). Over 95% of human adults are HHV-7 seropositive due to prior infection and thus persistently infected with HHV-7 (3). Indeed, primary herpesvirus infection typically results in a persistent infection during which periods of latency are interspersed with periods of reactivation (4). Although HHV-7 infection is generally considered to be benign, an increasing number of studies link the virus to more severe clinical syndromes such as transplant complications and neurological defects. Still, the virus is one of the least studied human herpesviruses. Indeed, on March 6th, 2024, merely 904 full-text articles were found using the search term “HHV-7” in PubMed (<https://pubmed.ncbi.nlm.nih.gov/>), compared to 3,932 items for “HHV-6” and 46,033 for “HHV-5.” The viral genome and particle structure (Fig. 1), including the major differences with those of HHV-6, and specific HHV-7-related clinical syndromes have been reviewed before (2, 5–8). However, a recent comprehensive overview of the viral pathogenesis and associated clinical manifestations is lacking. Here, we summarize the current state of knowledge on HHV-7 infection in humans to outline a hypothetical model for the viral pathogenesis and highlight areas for future research.

## VIRAL LIFE CYCLE

Herpesviral entry in host cells is mediated by interactions between viral envelope glycoproteins and molecules on the cell membrane. This complex process is divided into the following three steps: (i) virion attachment to the cell surface, (ii) virion interaction

**Editor** Suchetana Mukhopadhyay, Indiana University  
Bloomington, Bloomington, Indiana, USA


Address correspondence to Jolien Van Cleemput,  
[jolien.vandcleemput@ugent.be](mailto:jolien.vandcleemput@ugent.be).

The authors declare no conflict of interest.

See the funding table on p. 13.


**Published** 8 May 2024

Copyright © 2024 Verbeek et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**FIG 1** Human herpesvirus 7 (HHV-7) particle structure and genome. (A) Schematic overview of the HHV-7 particle structure with indication of major viral components. (B) Schematic representation of the genome arrangement of HHV-7 based on the NCBI reference genome NC\_001716.2. DRL (left), DRR (right): direct repeats. SCP: small capsid protein, pol: DNA polymerase, gB: glycoprotein B, gN: glycoprotein N, gO: glycoprotein O, gH: glycoprotein H, MCP: major capsid protein, kin: serine/threonine protein kinase, gM: glycoprotein M, gL: glycoprotein L, gQ: glycoprotein Q. Scale bars represent the number of base pairs. Figure made using [BioRender.com](https://www.biorender.com).

with a specific entry receptor, and (iii) virion internalization and membrane fusion. The studies of Black et al. (9) and Ablashi et al. (10) show transmission electron micrographs of these different steps during HHV-7 infection in lymphocytes. As illustrated in Fig. 2, HHV-7 initial adsorption to cells is likely mediated by the binding of viral envelope glycoproteins B and Q (gB and gQ) to cell-surface heparan sulfate proteoglycans (11, 12). Homologs of gB are found in all herpesviruses studied to date, but gQ is unique to HHV-6 and -7. The 65 kDa HHV-7 gQ is translated from multiply spliced mRNA encoded by ORF U100 (12, 13). In HHV-6, two transcripts of the U100 gene are produced, gQ1 (80 kDa) and gQ2 (37 kDa) (14). Whether this is also true for HHV-7 ORF100 gene products is unknown. Following initial attachment, HHV-7 virions firmly anchor onto a cellular receptor subsequently triggering fusion of the viral envelope and cellular membrane. CD4 is the sole known receptor for HHV-7. Indeed, overexpression of CD4 permits HHV-7 entry in non-permissive cell lines, while blocking CD4 using monoclonal antibodies or HIV gp120 inhibits HHV-7 entry (15–17). Still, additional unidentified cellular receptors likely also mediate HHV-7 entry, as the virus can productively infect cells lacking CD4 expression such as epithelial cells, endothelial cells, natural killer (NK) cells, megakaryocytes, dendritic cells, neurons, astrocytes, and oligodendrocytes (15, 16, 18–25). Notably, HHV-7 binding and entry are independent of HIV co-receptors CXCR4 and CCR5 (26, 27). Moreover, a low or mere expression of CD4 is not sufficient for productive viral infection, as CD4<sup>+</sup> HeLa, Jurkat, and THP1 cells do not support productive viral replication (15, 28). Whether these cells are not susceptible and do not support viral entry or are not permissive due to a block in viral replication is unknown. The putative viral ligand for CD4 is still unidentified, but plausible candidates are viral envelope glycoproteins gH, gL,



**FIG 2** Hypothetical model of HHV-7 entry in host cells. Virus attachment to, binding to, and entry in host cells occurs through the engagement of viral ligands and host cell surface receptors (upper panel). Close-up of these different steps according to models proposed for CD4<sup>+</sup> T cells and other cell types (lower panel). The figure was created using [BioRender.com](https://www.biorender.com).

or gO (11, 17). Since fusion products between the extracellular domain of HHV-7 gB and the Fc domain of human immunoglobulin G heavy chain  $\gamma 1$  do not bind CD4<sup>+</sup> T cells, gB likely does not engage CD4 (11). Co-expression of gB, gH, gL, and gO in HEK293T cells was necessary to induce membrane fusion and CD4 played a major role in this process, indicating that all four glycoproteins cooperate in the viral entry step (17). In general, herpesvirus gH and gL form a heterodimer complex that interacts with specific cell receptors which is then thought to induce a conformational change of the fusogen gB (pre- to post-fusion) to complete membrane fusion. In other betaherpesviruses (HCMV and HHV-6), gH/gL combines with additional viral envelope glycoproteins to form tri-, tetra-, and even pentamers to promote viral entry and provide receptor specificity (Table 1) (29, 30). Thus, we could speculate that HHV-7 may interact with CD4 through the engagement of the gH/gL/gO complex, subsequently triggering membrane fusion with the help of gB (11, 17, 31, 32). Alternatively, gH/gL/gQ and gB binding to putative receptors might also trigger viral entry into host cells, but evidence is currently lacking. In comparison, HHV-6 employs the multiprotein complex gH/gL/gQ1/gQ2 to interact with its primary receptor CD46 and subsequently trigger fusion (14, 33, 34). Although highly speculative, HHV-7 gH/gL associated with either gO or gQ may even provide additional receptor specificity, as was suggested for HHV-6 (Table 1) (35). As such, HHV-7 could

**TABLE 1** Comparison of viral ligands and cellular receptors implicated in attachment and entry of three major betaherpesviruses HCMV, HHV-6, and HHV-7<sup>a</sup>

	HCMV		HHV-6		HHV-7		Reference
	Viral ligand	Cellular receptor	Viral ligand	Cellular receptor	Viral ligand	Cellular receptor	
Attachment	gB and gM/gN	HSPGs	gQ1/gQ2?	HSPGs?	gB and gQ	HSPGs	(11, 12)
Binding and entry	gH/gL/gO	PDGFR- $\alpha$	gH/gL/gO	Unknown	gH/gL/gO?	CD4	(11, 17)
	gH/gL/pUL128/ pUL130/pUL131A	NRP2	gH/gL/gQ1/gQ2	CD46 (HHV-6A) and CD134 (HHV-6B)	gH/gL/gQ	Unknown	Speculative
	gB	None, EGFR, PDGFR $\alpha$ , integrins	gB	None or unknown	gB	None or unknown	(17)


<sup>a</sup>The former two have been extensively reviewed by Nishimura and Mori (30) and specific references are provided for HHV-7. HSPGs: heparan sulfate proteoglycans; PDGFR- $\alpha$ : platelet-derived growth factor receptor A; NRP2: neuropilin 2; EGFR: epidermal growth factor receptor; ?: research indicates, but does not prove, interaction.

employ gH/gL/gO for entry into CD4<sup>+</sup> cells and gH/gL/gQ for entry into other cell types (Fig. 1).

Following herpesvirus de-envelopment, which may occur either at the plasma or endosomal membranes, the nucleocapsid and tegument proteins are released inside the cytoplasm. The nucleocapsid travels towards the nuclear membrane, where it releases viral DNA into the nucleus *via* the nuclear pore complex. In the nucleus, viral transcription is initiated and proceeds *via* a cascade-like manner typical for herpesviruses (36). First, immediate early (alpha) genes are transcribed which encode proteins necessary for the expression of early (beta) genes. Early (beta) gene products regulate viral DNA replication and orchestrate the transcription of the late (gamma) genes encoding multiple viral structural proteins (e.g., capsid, tegument, and envelope proteins) (36, 37). Viral proteins are synthesized in the cytoplasm and capsid proteins reroute to the nucleus for assembly of capsids, prior to encapsidation of the viral DNA. The nucleocapsid then travels *via* the inner and outer nuclear membrane into the cytoplasm (9, 38). Nucleocapsids become decorated with tegument proteins inside the cytoplasm and acquire their envelope by budding into the Golgi apparatus. *In vitro* viral replication in T cells induces a typical cytopathic effect (CPE) characterized by the development of ballooning degeneration and multinucleated giant cells. The giant cells arise from single infected cells undergoing a process of polyploidization and not from the fusion of cells into syncytia as described for other herpesviruses (39). The majority of these multinucleated cells undergo necrotic cell lysis releasing virions in the extracellular space and thus represent a major source of infectious particles (40). Whether virions can also exit their host cell through vesicle-mediated exocytosis, as described for HHV-6, is not known (41). The complete HHV-7 replication cycle takes 3 to 5 days to complete.

## PATHOGENESIS INSIDE THE HOST

A hypothetical model for HHV-7 pathogenesis inside the human body is depicted in Fig. 3. Primary infection is established upon intake of virus-loaded bodily fluids. The exact portal of entry remains to be fully elucidated but most plausible candidates include the epithelial cells and/or CD4<sup>+</sup> T lymphocytes and macrophages of the tonsils located in the oral and nasopharyngeal mucosa. As suggested for EBV, viral progeny propagated in epithelial cells may be able to infect immune cells more efficiently and vice versa, fueling primary HHV-7 infection (42). Next, HHV-7-infected immune cells can travel toward draining lymph nodes through the action of HHV-7 U12 and U51. Indeed, these chemokine receptor-like proteins have been shown to interact with chemokine receptor (CCR) 7 agonists, including secondary lymphoid-tissue chemokine (SLC) and EBI1 ligand chemokine (ELC), stimulating homing and trafficking of lymphocytes into and within secondary lymphoid tissues (43). Furthermore, these virally encoded putative chemokine receptors also engage CCR4 agonists including chemokine ligands (CCL) 17 and CCL22 stimulating close interactions between T cells and T cells and macrophages (44). These close interactions could enable cell-associated spread of HHV-7 between neighboring cells, thereby avoiding the release of virus particles into the hostile extracellular environment.



**FIG 3** Hypothetical model of HHV-7 pathogenesis inside the human body. HHV-7 transmission (infection and shedding) occurs at the level of the oropharynx and salivary glands (left panel). HHV-7 disseminates to multiple organs inside the host. The gradient color (purple) indicates low to high evidence for HHV-7 detection in this organ, tissue, or bodily fluid (right panel). The figure was created using [BioRender.com](https://www.biorender.com).

Migration of infected peripheral blood mononuclear cells (PBMCs) into the bloodstream can initiate the viremic phase. Whether these cells actively shed free virus particles in plasma is not known. A previous study showed that plasma-derived viral DNA rather originates from cell lysis and release of viral nucleic acids than from virions (45). In addition, the adaptive immune system would rapidly neutralize free virus particles, suggesting that HHV-7, like other herpesviruses, initiates a cell-associated viremia. Besides, based on the homology between the roseoloviruses, HHV-7 might be able to refrain from viral protein expression at the cell surface and together with other immune-evasive strategies be capable of decoying patrolling immune cells in the blood and lymph system, as has been described for HHV-6.

HHV-7 disseminates to other parts of the body during the viremic phase. Immunohistochemistry studies show that HHV-7 can infect cells that are morphologically and phenotypically distinct from lymphocytes (e.g., dendritic and epithelial-like cells) in multiple tissues including lungs, skin, mammary glands, liver, and kidney (18, 24, 46). Whether productive HHV-7 replication takes place at these secondary sites is not known.

During primary infection and the viremic phase, a majority of infected immune cells will eventually succumb to infection, while other infected immune cells may be “saved” by HHV-7 to function as a life-long latency reservoir (40, 47). These cells still harbor viral DNA but do not produce viral transcripts or viral progeny. In line with this, viral DNA, but not viral transcripts, is frequently recovered from PBMCs of healthy individuals (37). Since resting T cells rarely shed infectious progeny, it is believed that these cells

act as a latent reservoir (9, 48). Viral reactivation may occur in case infected T cells become activated, as cognate antigen stimulation results in the onset of HHV-7 lytic replication and release of infectious virus particles (1, 9, 48, 49). Given their susceptibility to HHV-7 and their proven involvement in HCMV and HHV-6 latency, myeloid cells such as dendritic cells and monocytes could potentially also act as a site of latent infection (4, 24, 25, 50). Periodic reactivation allows the virus to transfer the infection to new hosts or fuel latency reservoirs within a host. In comparison with other herpesviruses, HHV-7 reactivation typically occurs during periods of immune suppression (51, 52). Still, HHV-7 reactivation does not always co-occur with immune suppression, as the virus is often detected in healthy individuals (18, 19, 53–64). How the virus exactly transfers infection from immune cells to salivary glands to shed viral progeny into the outer environment is currently unknown. As for EBV, infected leukocytes might reroute to the oro-respiratory tract and produce virions spiked with specific envelope glycoproteins (42, 65). For instance, gH/gL/gQ-pseudotyped virus particles might then be efficiently transferred to (salivary gland) epithelial cells, which could amplify the infection and shed a high viral load in salivary secretions to infect new hosts. Given the homology of U12 and U51 to HCMV U28, a CX3CR1 mimicker that binds fractalkine, fractalkine expression on salivary gland epithelial cells may additionally enhance virion-cell binding and thus the transfer of infection (66). However, Latchney et al. (67) could not identify a correlation between HHV-7 infection and fractalkine expression in human salivary glands, suggesting that fractalkine is not a prerequisite for HHV-7 infection. The majority of cell types residing in the salivary gland epithelium are susceptible to HHV-7, including ductal, cuboidal, and columnar epithelial cells as well as mucous and acinar cells (18, 19, 58, 68).

Multiple researchers suggest that besides the typical periods of herpesvirus latency and reactivation, HHV-7 may adopt a state of persistent infection. The high frequency at which HHV-7 is detected in saliva and salivary gland cells would indicate that persistent HHV-7 infection is established in the mouth (18, 19, 53–64). Still, there is no hard evidence for this hypothesis, as it may also be that reactivation events leading to transfer infection at the level of the salivary glands happen more frequently for HHV-7 compared to other herpesviruses.

## IMMUNE EVASION MECHANISMS

Over years of co-evolution with their respective host, herpesviruses have mastered various strategies to persist in an immunocompetent host population. The large herpesviral genome (145 kilobase pairs for HHV-7) consists of more than a hundred different genes providing an arsenal of viral proteins and noncoding RNAs to counteract the host immune system (69).

One of the most successful immune evasion mechanisms and hallmark of all herpesviruses is the establishment of a lifelong latency in their host following primary infection. Except for transcription of latency-associated genes, latent virus shuts down the transcription of its genome, allowing the virus to stay hidden from the host's immune surveillance. Upon primary infection, HHV-7 genomes are maintained as episomes in the nucleus of latently infected cells such as resting T cells (20, 37, 48). As described for other betaherpesviruses, HHV-7 may also be able to establish latency in bone marrow-derived hematopoietic progenitor cells (70, 71). The latent stage is sporadically interrupted by periods of lytic replication in a subset of latently infected cells, during which infectious progeny is produced. In turn, this may be transmitted to new hosts or used to restock sites of latent and/or persistent infection. This so-called viral reactivation arises from changing host factors promoting cell differentiation or activation. For instance, T-cell activation and inhibition of apoptosis facilitate the onset of HHV-7 lytic replication (48, 49). The activation state of T cells likely primes HHV-7 genomes for transcription either by stimulation of cellular transcription factors and/or inhibiting histone deacetylases (HDAC) which unwrap chromatin.

Another common herpesvirus strategy HHV-7 utilizes is the downregulation of class I major histocompatibility complex (MHC I) surface expression to avoid cytotoxic T

lymphocyte (CTL)-mediated killing of infected cells. To do so, the viral protein U21 associates with class I MHC molecules and a putative Golgi membrane protein or adaptor protein resulting in the sorting of these complexes to lysosomes, where they are degraded (72–78). Cells with reduced MHC I expression at the plasma membrane are normally recognized and cleared by host NK cells. However, HHV-7 circumvents NK-induced cell lysis by simultaneously rerouting NK-activating ligand UL-16 binding protein 1 (ULBP1) to the lysosomal compartment through the action of the same immune-evasion protein U21. In addition, U21 downregulates surface expression of the NK-activating ligands MHC class I polypeptide-related sequences A and B (MICA and B), resulting in the escape from NK-mediated cytotoxicity (79). Finally, U21 downregulates MHC class II proteins, additionally aiding HHV-7 in escaping helper immune cells (77). Notably, the host responds to HHV-7 infection by upregulating IL-15 production, which then results in an enhancement of NK cell activity (80). This is a neat example of the evolutionary arms race between host and virus, where each must counteract the other.

The onset of an adequate immune response may additionally be hampered by the function of HHV-7 U12 and U51 gene products. These viral proteins act as chemokine receptors that may divert chemokines from their natural ligands subverting a local immune response (43, 81, 82). Furthermore, viral replication induces apoptosis in bystander cells through the release of danger signals. For instance, HHV-7-infected cells upregulate the expression of TNF-related apoptosis-inducing ligand (TRAIL) inducing a cytopathic effect on adjacent bystander cells *via* activation of the TRAIL signaling pathway (47). Conversely, HHV-7-infected cells show a marked decrease in surface TRAIL-receptor 1 (TRAIL-R1) expression, thereby avoiding TRAIL-mediated cytotoxicity (47). This favors the survival of infected T cells while neighboring immune cells that may sense the virus are killed, enabling the virus to persist in its host. Even though these HHV-7-infected CD4 T cells are rescued from apoptosis, virus-induced changes perturb the proper immune functions of CD4 cells. For instance, HHV-7 replication in CD4<sup>+</sup> T cells is accompanied by a downregulation of CD4, CD3, and CXCR4 (27, 83–85). As such, as for HIV, the viral tropism for CD4 T cells itself may act as an immune-evasive strategy by reducing the repertoire of helper T cells *via* lytic replication and other immunomodulatory effects eventually causing immunodeficiency (40, 80).

Finally, direct cell-to-cell spread is another major strategy for HHV-7 to bypass the hostile extracellular environment, which contains phagocytes, antibodies, and complement. Indeed, the virus is best spread *via* cell-cell contact which may be facilitated by U54, as described for HHV-6 (10, 86).

## EPIDEMIOLOGY

HHV-7 specifically infects humans and is common throughout the globe. Specific IgG antibodies against HHV-7 can be found in over 90% of the adult human population (3). As for other herpesviruses, primary HHV-7 infection occurs most commonly in early childhood and lifelong persistence of the virus *via* a combination of latency and ongoing active replication in salivary glands enables the maintenance of a robust immune response for the life of the host (87). Young children become newly seropositive during the decline in maternal antibodies, with approximately 18%–43% of children becoming seropositive within the first year of life. By the second year, this proportion increases to 53%–67%, and by the third year, a substantial majority of children, approximately 93%, have acquired specific antibodies to HHV-7 (3, 88–91). Prevalence rates based on antibody detection are almost universal throughout the world (92, 93). One study reported that seasonal (autumn) and ethnicity factors (Black race) were associated with a higher prevalence of anti-HHV-7 antibody detection in children (94). However, antibody prevalence does not necessarily correlate with active HHV-7 infection and other characteristics associated with socioeconomic status may also have confounded these results.

HHV-7 infection mainly spreads *via* infectious bodily fluids such as saliva and respiratory secretions. Interestingly, an estimated 55% to 90% of people shed infectious

HHV-7 intermittently in saliva (18, 19, 53–57, 59–64). This might imply that HHV-7 rather establishes a persistent active infection instead of the typical herpesvirus latency state or that the virus repeatedly reactivates from latency in certain anatomical sites like salivary glands and tonsils (18, 19). Children can acquire the virus from their parents, siblings, or other children (95). Although it has not been proven, mother-to-child transmission may occur during birth or through breast milk. HHV-7 DNA has been detected in breast milk samples and viral proteins have been found in mammary glands (18, 96). However, antibodies to HHV-7 in breast milk may also protect against infection since breastfeeding has been associated with a lower risk of early acquisition of HHV-7 infection (94). Furthermore, HHV-7 DNA has been detected in 3%–10% of cervical swabs obtained from women in their third trimester of pregnancy, but from none of the swabs of non-pregnant control women, suggesting that pregnancy may be associated with reactivation of HHV-7 (97–99). Still, it is unclear whether perinatal transmission can occur through contact with infected maternal secretions, and neonatal infections with HHV-7 have not been reported to date (100). Urine and stool only sporadically contain traces of HHV-7 DNA and are thus unlikely to be a source of transmission (53–55, 101, 102). Finally, HHV-7's T-lymphotropic character and occasional presence in plasma suggest the possibility of viral transmission during blood transfusions or organ transplantations, but well-documented case reports or series are missing (103–105).

## CLINICAL MANIFESTATIONS

It is often difficult to identify direct causality between herpesviruses and clinical manifestations due to the ubiquitous nature of herpesviruses and their capacity to induce a lifelong infection where only certain individuals experience problems either through direct cytopathology or by triggering a pathological immune response (87). Therefore, we have used a set of criteria based on the revised postulates of Koch that were suggested by Komaroff et al. (106), to evaluate associations between HHV-7 and different clinical manifestations (Tables 2 and 3).

### Dermatological diseases

HHV-7 has been linked to a number of dermatological diseases, although its role in the pathophysiology of these illnesses is not fully understood.

HHV-7, like HHV-6, has a proven association with roseola infantum, also known as exanthem subitum or sixth disease, although HHV-7 is less frequently linked to the disease compared to HHV-6 (102, 107, 108, 128, 129). Exanthem subitum is a common childhood illness that mostly develops before the age of 3 and is non-discriminatory in gender and location. Around 50% of HHV-7 infections in children induce exanthem subitum and symptoms vary from absence to a fever and/or a rash that lasts one to several days (128, 129). The rash is characterized by non-pruritic papules and macules and typically starts on the trunk and can spread to the neck, extremities, and face. Other symptoms include anorexia, leukopenia, mild diarrhea, palpebral edema, mild inflammation of the pharynx, and mild occipital and cervical lymphadenopathy. Serious complications are rare but may include febrile seizures and/or status epilepticus (89, 138). Febrile seizures occur in 2%–5% of children younger than the age of 5 and around 7% of these cases can be linked to HHV-7 viremia (108, 138). For HHV-6, these febrile seizures have been linked to a dysfunctional blood-brain barrier caused by virus-induced rises in serum matrix metalloproteinases (171). Whether this also occurs during HHV-7 infection has not been studied. Most cases of roseola infantum improve on their own. Virus replication in the naso- and oropharynx and/or draining lymph nodes along with the viremic phase account for most symptoms. Histopathological examination of viral exanthem usually shows normal epidermis with sparse perivascular infiltration of lymphocytes and/or vasculitis (172).

As shown in Table 2, a more debated association of both HHV-7 and HHV-6 is pityriasis rosea, a common skin rash with a prevalence of 1.3% that typically occurs in young



**TABLE 2** Criteria helpful in evaluating the causal role of HHV-7 in dermatological diseases, based on the revised postulates of Koch suggested by Komaroff et al. (106)<sup>a</sup>

	Roseola infantum	Pityriasis rosea	Atypical exanthem	PPGSS	DIHS/DRESS	TEN	Lichen planus
HHV-7 nucleic acid is present in diseased tissue/individuals.	Blood (89, 102, 107, 108)	Blood and skin (109–112) Negative evidence of blood and skin (113–115)	Blood (116) Negative evidence skin (116)	Blood (116–118) Negative evidence skin (116)	Blood and skin (119–123)	Throat swab (124)	Skin (24, 46, 125–127)
The amount of HHV-7 nucleic acid in diseased tissue and/or antibody levels correlates with the severity of the disease.	Nucleic acid and antibody levels (89, 107, 108, 128, 129)	Nucleic acid and antibody levels (110, 111, 117, 130) Negative evidence of nucleic acid and antibody levels (113–115)	No evidence	Antibody levels (118, 131)	No evidence	Negative evidence of antibody levels (132)	Nucleic acid levels (24, 46, 125, 127)
HHV-7 mRNA, antigens, or infectious virions are present in diseased tissue.	Antigens and infectious virions (89, 102, 107, 108, 129)	mRNA and antigens (110, 111)	No evidence	No evidence	No evidence	No evidence	Antigens (24, 46)
Exposure to and then the presence of the viruses and their gene products in affected tissue precede the development of the disease or seroconversion is detected (temporal relationship).	Seroconversion (89, 107, 108, 128, 129)	Negative evidence seroconversion (112)	No evidence	No evidence	Seroconversion (119–121, 123)	T-cell immunity (124) Seroconversion (133)	Nucleic acids and antigens disappear upon remission (46)
Infectious agents other than HHV-7 are not generally detected in diseased tissue in a substantial number of cases.	Positive evidence (107, 129) Negative evidence (HHV-6) (89, 102, 108, 128)	Positive evidence (111) Negative evidence (HHV-6) (110, 114)	Negative evidence (other viruses, bacteria, and parasites) (134)	Positive evidence (116, 117) Negative evidence (Parvovirus B19) (117, 118)	Positive evidence (119, 121) Negative evidence (other herpesviruses) (119, 120, 123, 133)	Negative evidence (other herpesviruses, coxsackievirus A6, and bacterial infections) (124, 133)	Positive evidence (24) Negative evidence (126)
HHV-7 affects cellular function in diseased tissue in a manner able to cause or augment the disease pathology ( <i>in vitro</i> or <i>in vivo</i> studies).	Lymphocyte CPE (89, 102)	Lymphocyte CPE (109)	No evidence	No evidence	No evidence	No evidence	No evidence
Specific antiviral therapy reduces viral load in diseased tissue or blood and is followed by clinical improvement.	No evidence	Positive evidence (135–137)	No evidence	No evidence	No evidence	No evidence	No evidence

<sup>a</sup>All evidence cited is positive in support of the assertion unless specifically identified as negative evidence. PPGSS: papular purpuric gloves and socks syndrome; DIHS: drug-induced hypersensitivity syndrome; DRESS: drug reaction with eosinophilia and systemic symptoms; TEN: toxic epidermal necrolysis; CPE: cytopathogenic effect.

**TABLE 3** Criteria helpful in evaluating the causal role of HHV-7 in neurological diseases, based on the revised postulates of Koch suggested by Komaroff et al. (106)<sup>a</sup>

	Febrile seizures/epilepsia	Encephalitis	Meningitis	Myelitis	Neuritis	Hippocampal sclerosis	Meningo-/myelo-radiculopathy
HHV-7 nucleic acid is present in diseased tissue/individuals.	Blood (89, 128, 138–140) CSF (6, 140–144)	Blood (140, 145, 146) CSF (6, 140–143, 146–158) Brain tissue (22, 153, 159)	Blood (140) CSF (140, 141, 147, 148, 149, 156, 160–162)	CSF (141, 147, 148, 161, 163, 164)	CSF (141, 144, 160, 165)	Hippocampus (166)	CSF (147, 151, 165, 167, 168)
The amount of HHV-7 nucleic acid in diseased tissue and/or antibody levels correlates with the severity of the disease.	Nucleic acid levels (145)	Nucleic acid and antibody levels (141, 145, 148, 22, 159, 169) 129, 146	Nucleic acid levels (141)	No evidence	Nucleic acid levels (141)	Nucleic acid levels (166)	No evidence
HHV-7 mRNA, antigens, or infectious virions are present in diseased tissue.	mRNA and infectious virions (138, 139)	Antigens (22)	mRNA (161)	mRNA (161)	No evidence	Antigens (166)	No evidence
Exposure to and then the presence of the viruses and their gene products in affected tissue precede the development of the disease or seroconversion is detected (temporal relationship).	Seroconversion (128, 145)	Seroconversion (146, 147, 149–151, 170)	Seroconversion (160)	No evidence	Seroconversion (160, 165)	No evidence	Seroconversion (147, 151, 165)
Infectious agents other than HHV-7 are not generally detected in diseased tissue in a substantial number of cases.	Positive evidence (129, 139, 140, 144) Negative evidence (HHV-6) (128, 138, 145)	Positive evidence (22, 140, 144, 146, 151, 152, 155, 158) Negative evidence (156) (145, 148, 154, 156, 157, 159)	Positive evidence (140, 160, 162) Negative evidence (156)	Positive evidence (163)	Positive evidence (144, 160) Negative evidence (165)	No evidence	Positive evidence (151, 168) Negative evidence (165)
HHV-7 affects cellular function in diseased tissue in a manner able to cause or augment the disease pathology ( <i>in vitro</i> or <i>in vivo</i> studies).	Lymphocyte CPE (89, 102)	No evidence	No evidence	No evidence	No evidence	No evidence	No evidence
Specific antiviral therapy reduces viral load in diseased tissue or blood and is followed by clinical improvement.	Positive evidence (6, 143, 144)	Positive evidence (6, 143, 144, 148, 152, 154)	Positive evidence (148, 161)	Positive evidence (163)	Positive evidence (144)	No evidence	Negative evidence (167)

<sup>a</sup>All evidence cited is positive in support of the assertion unless specifically identified as negative evidence. CSF: cerebrospinal fluid; CPE: cytopathogenic effect.

adults, usually lasts less than 3 months and disappears without treatment (109, 110, 113–115, 130, 173). The condition often starts with a single, slightly raised, scaly patch called the “herald patch” on the torso, followed by the appearance of smaller similar patches on the torso and extremities. HHV-7 antigens and DNA have been detected in up to 83% of skin lesions of pityriasis rosea and to a lesser extent in other dermatites (109–111, 117, 174, 175). Furthermore, higher viral loads in PBMCs and/or plasma are observed in cases of pityriasis rosea compared to controls. However, viral DNA and antigens can also be retrieved from non-lesional skin or control subjects, and it is not always easy to distinguish latent from active viral replication (110, 113, 174). Therefore, the exact role of HHV-7 in the pathogenesis of pityriasis rosea is still up for debate. An association seems likely, but the etiologic mechanism remains unknown.

The presence of HHV-7 has also been linked to several other dermatitis including atypical exanthems (116), papular purpuric gloves and socks syndrome (PPGSS) (116–118, 131), drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) (119–123, 133), immune-mediated toxic epidermal necrolysis (124, 133), and lichen planus (24, 46, 125–127). The extent to which HHV-7 infection directly contributes to these syndromes acts as an exogenous antigen in immune reactions, or if HHV-7 reactivation is simply a side reaction to the disease remains largely unknown (Table 2).

## Neurological disorders

As described above, seizures are not an uncommon complication of HHV-7 infection and are often associated with viral-induced high fever (i.e., febrile seizures) (89, 128, 139, 141, 142). Congruent with febrile seizures, HHV-7 viremia has also been associated with febrile status epilepticus (138). One study also linked the presence of HHV-7 DNA and antigens in the brain to inflammatory-mediated hippocampal sclerosis and drug-resistant epilepsy (166). Other neurological disorders such as encephalitis, meningitis, myelitis, cerebellitis, neuritis, and meningo- or myeloradiculopathy (e.g., Guillian Barré syndrome) have also been observed during ongoing HHV-7 infection (6, 128, 129, 139–141, 143–158, 160–165, 167, 168, 170). In most cases, CNS manifestations ranging from nausea, sensitivity to light, and a stiff neck to ataxia and paralysis were accompanied by the detection of HHV-7 nucleic acids in cerebrospinal fluid (CSF) and/or synthesis of intrathecal anti-HHV-7 antibodies (6, 129, 140, 141, 143–158, 160–164, 167, 168). Of note, HHV-7-specific antibodies or DNA were usually not accompanied by the presence of other viral DNA or antibodies, ruling out potential leakage through the blood-brain barrier (BBB) and indicating that HHV-7 can invade the nervous system. In addition, multiple studies have detected HHV-7 DNA and antigens in the brains of persons with and without neurological pathologies (22, 153, 159, 166, 169). More precisely, HHV-7 DNA has been retrieved from the meninges (dura mater and pia mater) (159), frontal lobe (22, 159, 169), temporal lobe (22, 159, 169), occipital lobe (169), parietal lobe (169), hippocampus (159, 166), olfactory tract (159), optic tract (159), cerebellum (169), and brain stem (153). Viral proteins have been reported in astrocytes, oligodendrocytes, as well as neurons (22, 166). How exactly HHV-7 reaches the brain parenchyma is unknown, but this presumably occurs either *via* retro- and anterograde viral transport through peripheral nerves (e.g., olfactory or optic tract) or *via* the vascular system where the virus passes through the BBB either cell-free or cell-associated. Upon reaching the nervous system, local viral replication with accompanying damage and/or vasculitis accompanied by a focal impairment of blood flow can cause neurological damage resulting in neurological disease. Alternatively, as an exogenous antigen, HHV-7 may also be a pathological factor in the development of immune-related neurological damage.

The above-described case studies suggest, but do not prove, a neurotropic and neuropathogenic potential of HHV-7 (Table 3). Still, unlike HHV-6, HHV-7 is not a common cause of encephalitis and *in vitro* replication in neuronal cell lines has not been reported (176). The development of neurological disease is likely multifactorial depending not only on the viral strain but also on host factors such as age and immune status.

As described for other herpesviruses, primary HHV-7 infections delayed into adolescence might cause more severe neurological diseases than those occurring in early childhood (140, 143, 144, 147, 149, 155, 168). This is because the aggressive inflammatory response produced by a more mature immune system can paradoxically lead to more tissue damage. Conversely, the inability of the immune system to locally contain HHV-7 infection in immunocompromised individuals [e.g., corticosteroids, chemotherapy, transplantation, human immunodeficiency virus (HIV) infection] also predisposes patients to more severe neurological diseases (153, 154, 160, 163, 164).

### Other clinical associations

HHV-7 infection has been linked to various clinical syndromes not only in individuals undergoing transplantations but also in non-transplant settings.

Transplantations are preceded by aggressive conditioning regimens that deplete existing bone marrow and immune cells. Suppression of the recipient's immune system is necessary to maximize the chances of engraftment and long-term function of the transplanted organ or cells. As stated above, immune suppression may evoke reactivation events of endogenous herpesviruses or predispose patients to acquiring (re)infections from infected individuals or even donor transplants. HHV-7 reactivation or (re)infection has been linked to various complications in transplant recipients with or without other concomitant infections, including CNS disease (see above), hepatitis, bronchiolitis, pneumonia, transplant rejection, and CMV disease (177–183). These case studies have associated HHV-7 with transplant complications based on the detection of HHV-7 DNA in either the blood or CSF of the patients but do not describe the underlying mechanisms. Furthermore, the exact incidence of specific HHV-7-induced transplant complications remains uncertain.

HHV-7 infection has also been implicated in diverse clinical syndromes beyond the context of transplantations and in immunocompetent hosts, including mononucleosis-like illnesses (184–187), acute respiratory distress syndrome and interstitial pneumonia (188, 189), hepatitis (190), myocarditis (191, 192), fibromyalgia (193), connective tissue disease (194), and periodontitis (195). In these case studies, HHV-7 diagnosis was based on seroconversion and/or detection of HHV-7 DNA in several anatomical compartments (blood, lungs, BAL, liver biopsies, etc.). Still, whether the viral DNA derives from circulating blood-derived PBMCs or tissue-resident cells is unclear. Currently, the causative role of HHV-7, either alone or in conjunction with other viruses/factors, in causing these syndromes, remains solely speculative, as proving causation remains complicated, partially due to the regular detection of HHV-7 in healthy people.

### CONCLUSIONS, KNOWLEDGE GAPS, AND RECOMMENDATIONS FOR FUTURE RESEARCH

Despite its initial identification in 1990, HHV-7 remains an understudied herpesvirus ominously present in the human population. HHV-7, like other herpesviruses, typically presents minimal or no issues when acquired naturally during early childhood and remains in a state of equilibrium with its host. However, a slight disruption in this equilibrium, such as delayed infections occurring during adolescence or immune suppression, can shift the balance toward a more pronounced and severe clinical outcome. Still, little is known about the etiological nature of most of these manifestations. To better understand the critical interplay between virus and host, we need to gain more insights in viral pathogenesis. More precisely, studies should investigate how and where HHV-7 replicates and hides inside its host and how the host immune system responds to incoming viruses. This information could reveal triggers of specific clinical syndromes of severe HHV-7-induced manifestations, leading to the identification of new cures, treatments, and/or prevention strategies, ultimately benefitting patients.

One of the major limitations in HHV-7 research is the species-specific nature of HHV-7 and thus the lack of suitable *in vivo* models to study the viral pathogenesis.

Unfortunately, well-controlled inoculation experiments in naïve hosts cannot be tested ethically in patients and, therefore, we must rely only on case series and *in vitro* models. Still, case studies lack a well-controlled experimental setup where the early phase of infection has usually already passed upon clinical presentation, and invasive sampling to study viral dissemination simply cannot be done. Furthermore, the complex interplay between HHV-7-infected and neighboring cells in a 3D environment, as well as the inflammatory processes triggered by HHV-7 cannot be accurately recapitulated *in vitro*. Still, there are solutions and alternatives to explore HHV-7 pathogenesis in animal models. First, as for HIV, a humanized mouse model in which human immune cells are engrafted could potentially be used to study HHV-7 infection, as described for HHV-6 (196). Notably, viral transfer between different anatomical compartments cannot be replicated in the latter model, since non-immune cells (e.g., neurons and epithelial cells) remain mouse-derived and might not support viral replication. Inoculating mice with a mouse-specific roseolovirus closely related to HHV-6 and HHV-7 (e.g., murine roseolovirus or MRV) might be an interesting substitute to broaden insights into HHV-7 immunopathogenesis (197). Similarly, murine CMV is used to mimic HCMV pathogenesis in mice (198). Alternatively, pigtailed macaque roseolovirus or *Macaca nemestrina* herpesvirus 7 (MneHV7) is another roseolovirus that even more closely resembles HHV-7 than MRV and could be used to infect non-human primates (199). Besides *in vivo* models, *ex vivo* models where a 3D architecture between different cell types is reconstructed, (e.g., explant, organoid, transwell, and trichamber models) could also partly mimic the interplay between epithelial cells and immune cells or even construct segmented environments between different cell types to study viral transfer infection (200, 201).

Finally, our review also identified many knowledge gaps in the HHV-7 life cycle, especially the entry step. With the rise of versatile gene-editing tools such as CRISPR-Cas9, new viral mutants, and cellular gene knockouts could more easily be generated to further unravel these steps (200). Identifying additional receptors might, for instance, provide new targets for cure interventions in severe clinical manifestations related to HHV-7 infection (e.g., neurological disorders and transplant complications).

Together, HHV-7 has been associated with a variety of clinical syndromes suggesting it has a broader impact on human health than previously thought. However, new *ex vivo* and *in vivo* experiments are urgently needed to broaden our insights into the viral pathogenesis and find new intervention strategies.

## ACKNOWLEDGMENTS

The authors thank Prof. Dr. Sarah Gerlo for her critical comments on the paper.

J.V.C. was supported by the Research Foundation Flanders (FWO grant 12ZB921N). R.V. was supported by the Research Foundation Flanders (FWO grant 1SHDF24N).

## AUTHOR AFFILIATION

<sup>1</sup>HIV Cure Research Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

## AUTHOR ORCIDs

Rianne Verbeek  <http://orcid.org/0000-0001-8731-2987>

Jolien Van Cleemput  <http://orcid.org/0000-0003-1598-3057>

## FUNDING

Funder	Grant(s)	Author(s)
Fonds Wetenschappelijk Onderzoek (FWO)	12ZB921N	Jolien Van Cleemput
Fonds Wetenschappelijk Onderzoek (FWO)	1SHDF24N	Rianne Verbeek

## REFERENCES

- Frenkel N, Schirmer EC, Wyatt LS, Katsafanas G, Roffman E, Danovich RM, June CH. 1990. Isolation of a new herpesvirus from human CD4<sup>+</sup> T cells. *Proc Natl Acad Sci U S A* 87:748–752. <https://doi.org/10.1073/pnas.87.2.748>
- Caselli E, Luca D. 2007. Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7. *New Microbiol* 30:173–188.
- Wyatt LS, Rodriguez WJ, Balachandran N, Frenkel N. 1991. Human herpesvirus 7: antigenic properties and prevalence in children and adults. *J Virol* 65:6260–6265. <https://doi.org/10.1128/JVI.65.11.6260-6265.1991>
- Kondo K, Yamanishi K. 2007. HHV-6A, 6B, and 7: molecular basis of latency and reactivation, p 843–849. In *Human herpesviruses: biology, therapy, and immunoprophylaxis*
- Agut H, Bonnafous P, Gautheret-Dejean A. 2016. Human herpesviruses 6A, 6B, and 7. *Microbiol Spectr* 4. <https://doi.org/10.1128/microbiol-spec.DMIH2-0007-2015>
- Li Y, Qu T, Li D, Jing J, Deng Q, Wan X. 2022. Human herpesvirus 7 encephalitis in an immunocompetent adult and a literature review. *Virol J* 19:200. <https://doi.org/10.1186/s12985-022-01925-9>
- Wolz MM, Sciallis GF, Pittelkow MR. 2012. Human herpesviruses 6, 7, and 8 from a dermatologic perspective. *Mayo Clin Proc* 87:1004–1014. <https://doi.org/10.1016/j.mayocp.2012.04.010>
- Ljungman P. 2002. Beta-herpesvirus challenges in the transplant recipient. *J Infect Dis* 186:S99–S109. <https://doi.org/10.1086/342962>
- Black JB, Burns DA, Goldsmith CS, Feorino PM, Kite-Powell K, Schinazi RF, Krug PW, Pellett PE. 1997. Biologic properties of human herpesvirus 7 strain SB. *Virus Res* 52:25–41. [https://doi.org/10.1016/s0168-1702\(97\)00102-0](https://doi.org/10.1016/s0168-1702(97)00102-0)
- Ablashi DV, Handy M, Bernbaum J, Chatlynne LG, Lapps W, Kramarsky B, Berneman ZN, Komaroff AL, Whitman JE. 1998. Propagation and characterization of human herpesvirus-7 (HHV-7) isolates in a continuous T-lymphoblastoid cell line (SupT1). *J Virol Methods* 73:123–140. [https://doi.org/10.1016/s0166-0934\(98\)00037-8](https://doi.org/10.1016/s0166-0934(98)00037-8)
- Secchiero P, Sun D, De Vico AL, Crowley RW, Reitz MS, Zauli G, Lusso P, Gallo RC. 1997. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. *J Virol* 71:4571–4580. <https://doi.org/10.1128/JVI.71.6.4571-4580.1997>
- Skrincosky D, Hocknell P, Whetter L, Secchiero P, Chandran B, Dewhurst S. 2000. Identification and analysis of a novel heparin-binding glycoprotein encoded by human herpesvirus 7. *J Virol* 74:4530–4540. <https://doi.org/10.1128/jvi.74.10.4530-4540.2000>
- Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X, Dewhurst S. 2001. Epitope mapping of human herpesvirus-7 gp65 using monoclonal antibodies. *Arch Virol* 146:1705–1722. <https://doi.org/10.1007/s007050170058>
- Akkapaiboon P, Mori Y, Sadaoka T, Yonemoto S, Yamanishi K. 2004. Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope. *J Virol* 78:7969–7983. <https://doi.org/10.1128/JVI.78.15.7969-7983.2004>
- Yasukawa M, Inoue Y, Ohminami H, Sada E, Miyake K, Tohyama T, Shimada T, Fujita S. 1997. Human herpesvirus 7 infection of lymphoid and myeloid cell lines transduced with an adenovirus vector containing the CD4 gene. *J Virol* 71:1708–1712. <https://doi.org/10.1128/JVI.71.2.1708-1712.1997>
- Lusso P, Secchiero P, Crowley RW, Garzino-Demo A, Berneman ZN, Gallo RC. 1994. CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. *Proc Natl Acad Sci U S A* 91:3872–3876. <https://doi.org/10.1073/pnas.91.9.3872>
- XU J, Yao K, Dou J, Qin J, XU W, Chen Y, Yin Q, Zhou F. 2007. Human herpesvirus 7 glycoprotein B (gB), gH, gL, gO can mediate cell fusion. *Prog Biochem Biophys* 34:1202–1209.
- Kempf W, Adams V, Mirandola P, Menotti L, Di Luca D, Wey N, Müller B, Campadelli-Fiume G. 1998. Persistence of human herpesvirus 7 in normal tissues detected by expression of a structural antigen. *J Infect Dis* 178:841–845. <https://doi.org/10.1086/515339>
- Yadav M, Nambiar S, Khoo SP, Yaacob HB. 1997. Detection of human herpesvirus 7 in salivary glands. *Arch Oral Biol* 42:559–567. [https://doi.org/10.1016/s0003-9969\(97\)00049-6](https://doi.org/10.1016/s0003-9969(97)00049-6)
- Miyake F, Yoshikawa T, Sun H, Kakimi A, Ohashi M, Akimoto S, Nishiyama Y, Asano Y. 2006. Latent infection of human herpesvirus 7 in CD4<sup>+</sup> T lymphocytes. *J Med Virol* 78:112–116. <https://doi.org/10.1002/jmv.20511>
- Bortolotti D, Gentili V, Caselli E, Siculo M, Soffritti I, D'Accolti M, Barao I, Rotola A, Di Luca D, Rizzo R. 2020. DNA sensors' signaling in NK cells during HHV-6A, HHV-6B and HHV-7 infection. *Front Microbiol* 11:226. <https://doi.org/10.3389/fmicb.2020.00226>
- Skuja S, Svirskis S, Murovska M. 2021. Human herpesvirus-6 and -7 in the brain microenvironment of persons with neurological pathology and healthy people. *Int J Mol Sci* 22:1–19. <https://doi.org/10.3390/ijms22052364>
- Gonelli A, Mirandola P, Grill V, Secchiero P, Zauli G. 2002. Human herpesvirus 7 infection impairs the survival/differentiation of megakaryocytic cells. *Haematologica* 87:1223–1225.
- De Vries HJC, van Marle J, Teunissen MBM, Picavet D, Zоргdrager F, Bos JD, Weel J, Cornelissen M. 2006. Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. *Br J Dermatol* 154:361–364. <https://doi.org/10.1111/j.1365-2133.2005.06999.x>
- Zhang Y, de Bolle L, Aquaro S, van Lommel A, De Clercq E, Schols D. 2001. Productive infection of primary macrophages with human herpesvirus 7. *J Virol* 75:10511–10514. <https://doi.org/10.1128/JVI.75.21.10511-10514.2001>
- Zhang Y, Hatse S, De Clercq E, Schols D. 2000. CXC-chemokine receptor 4 is not a coreceptor for human herpesvirus 7 entry into CD4<sup>+</sup> T cells. *J Virol* 74:2011–2016. <https://doi.org/10.1128/jvi.74.4.2011-2016.2000>
- Yasukawa M, Hasegawa A, Sakai I, Ohminami H, Arai J, Kaneko S, Yakushiji Y, Maeyama K, Nakashima H, Arakaki R, Fujita S. 1999. Down-regulation of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7. *J Immunol* 162:5417–5422. <https://doi.org/10.4049/jimmunol.162.9.5417>
- Berneman ZN, Ablashi DV, Li G, Eger-Fletcher M, Reitz MS, Hung CL, Brus I, Komaroff AL, Gallo RC. 1992. Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. *Proc Natl Acad Sci U S A* 89:10552–10556. <https://doi.org/10.1073/pnas.89.21.10552>
- Zhong L, Zhang W, Krummenacher C, Chen Y, Zheng Q, Zhao Q, Zeng M-S, Xia N, Zeng Y-X, Xu M, Zhang X. 2023. Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents. *Trends Microbiol* 31:788–804. <https://doi.org/10.1016/j.tim.2023.03.001>
- Nishimura M, Mori Y. 2019. Entry of betaherpesviruses. *Adv Virus Res* 104:283–312. <https://doi.org/10.1016/bs.aivir.2019.05.005>
- Sadaoka T, Yamanishi K, Mori Y. 2006. Human herpesvirus 7 U47 gene products are glycoproteins expressed in virions and associate with glycoprotein H. *J Gen Virol* 87:501–508. <https://doi.org/10.1099/vir.0.81374-0>
- Mukai T, Hata A, Isegawa Y, Yamanishi K. 1997. Characterization of glycoprotein H and L of human herpesvirus 7. *Microbiol Immunol* 41:43–50. <https://doi.org/10.1111/j.1348-0421.1997.tb01171.x>
- Santoro F, Greenstone HL, Insinga A, Liszewski MK, Atkinson JP, Lusso P, Berger EA. 2003. Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46\*. *J Biol Chem* 278:25964–25969. <https://doi.org/10.1074/jbc.M302373200>
- Mori Y, Yang X, Akkapaiboon P, Okuno T, Yamanishi K. 2003. Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46. *J Virol* 77:4992–4999. <https://doi.org/10.1128/jvi.77.8.4992-4999.2003>
- Mori Y, Akkapaiboon P, Yonemoto S, Koike M, Takemoto M, Sadaoka T, Sasamoto Y, Konishi S, Uchiyama Y, Yamanishi K. 2004. Discovery of a second form of tripartite complex containing gH-gL of human herpesvirus 6 and observations on CD46. *J Virol* 78:4609–4616. <https://doi.org/10.1128/jvi.78.9.4609-4616.2004>
- Krug LT, Pellett PE. 2014. Roseolovirus molecular biology: recent advances. *Curr Opin Virol* 9:170–177. <https://doi.org/10.1016/j.coviro.2014.10.004>

37. Menegazzi P, Galvan M, Rotola A, Ravaoli T, Gonelli A, Cassai E, Di Luca D. 1999. Temporal mapping of transcripts in human herpesvirus-7. *J Gen Virol* 80:2705–2712. <https://doi.org/10.1099/0022-1317-80-10-2705>
38. Klussmann JP, Krueger E, Sloots T, Berneman Z, Arnold G, Krueger GRF. 1997. Ultrastructural study of human herpesvirus-7 replication in tissue culture. *Virchows Archiv* 430:417–426. <https://doi.org/10.1007/s004280050051>
39. Secchiero P, Bertolaso L, Casareto L, Gibellini D, Vitale M, Bemis K, Aleotti A, Capitani S, Franchini G, Gallo RC, Zauli G. 1998. Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to dysregulation of cdc2 and cyclin B and polyploidization of CD4<sup>+</sup> T cells. *Blood* 92:1685–1696. <https://doi.org/10.1182/blood.V92.5.1685>
40. Secchiero P, Flamand L, Gibellini D, Falcieri E, Robuffo I, Capitani S, Gallo RC, Zauli G. 1997. Human herpesvirus 7 induces CD4<sup>+</sup>T-cell death by two distinct mechanisms: necrotic lysis in productively infected cells and apoptosis in uninfected or nonproductively infected cells. *Blood* 90:4502–4512. <https://doi.org/10.1182/blood.V90.11.4502>
41. Mori Y, Koike M, Moriishi E, Kawabata A, Tang H, Oyaizu H, Uchiyama Y, Yamanishi K. 2008. Human herpesvirus - 6 induces MVB formation, and virus egress occurs by an exosomal release pathway. *Traffic* 9:1728–1742. <https://doi.org/10.1111/j.1600-0854.2008.00796.x>
42. Borza CM, Hutt-Fletcher LM. 2002. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. *Nat Med* 8:594–599. <https://doi.org/10.1038/nm0602-594>
43. Tadagaki K, Nakano K, Yamanishi K. 2005. Human herpesvirus 7 open reading frames U12 and U51 encode functional  $\beta$ -chemokine receptors. *J Virol* 79:7068–7076. <https://doi.org/10.1128/JVI.79.11.7068-7076.2005>
44. Yoshie O, Matsushima K. 2015. CCR4 and its ligands: from bench to bedside. *Int Immunol* 27:11–20. <https://doi.org/10.1093/intimm/dxu079>
45. Achour A, Boutolleau D, Slim A, Agut H, Gautheret-Dejean A. 2007. Human herpesvirus-6 (HHV-6) DNA in plasma reflects the presence of infected blood cells rather than circulating viral particles. *J Clin Virol* 38:280–285. <https://doi.org/10.1016/j.jcv.2006.12.019>
46. de Vries HJC, Teunissen MBM, Zorgdrager F, Picavet D, Cornelissen M. 2007. Lichen planus remission is associated with a decrease of human herpes virus type 7 protein expression in plasmacytoid dendritic cells. *Arch Dermatol Res* 299:213–219. <https://doi.org/10.1007/s00403-007-0750-0>
47. Secchiero P, Mirandola P, Zella D, Celeghini C, Gonelli A, Vitale M, Capitani S, Zauli G. 2001. Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4<sup>+</sup> T cells. *Blood* 98:2474–2481. <https://doi.org/10.1182/blood.v98.8.2474>
48. Katsafanas GC, Schirmer EC, Wyatt LS, Frenkel N. 1996. *In vitro* activation of human herpesviruses 6 and 7 from latency. *Proc Natl Acad Sci U S A* 93:9788–9792. <https://doi.org/10.1073/pnas.93.18.9788>
49. Secchiero P, Bertolaso L, Gibellini D, Ricci D, Bemis K, Capitani S, Gallo RC, Zauli G. 1998. Enforced expression of human *bcl - 2* in CD4<sup>+</sup> T cells enhances human herpesvirus 7 replication and induction of cytopathic effects. *Eur J Immunol* 28:1587–1596. [https://doi.org/10.1002/\(SICI\)1521-4141\(199805\)28:05<1587::AID-IMMU1587>3.0.CO;2-#](https://doi.org/10.1002/(SICI)1521-4141(199805)28:05<1587::AID-IMMU1587>3.0.CO;2-#)
50. Elder E, Sinclair J. 2019. HCMV latency: what regulates the regulators? *Med Microbiol Immunol* 208:431–438. <https://doi.org/10.1007/s00430-019-00581-1>
51. Raposo JV, Sarmento D, Pinto R, Lopes AO, Gallottini M, Tozetto-Mendoza TR, Braz-Silva PH, de Paula VS. 2020. Longitudinal study on oral shedding of human betaherpesviruses 6 and 7 in renal transplant recipients reveals active replication. *J Oral Microbiol* 12:1785801. <https://doi.org/10.1080/20002297.2020.1785801>
52. Kempf W, Müller B, Maurer R, Adams V, Campadelli Fiume G. 2000. Increased expression of human herpesvirus 7 in lymphoid organs of AIDS patients. *J Clin Virol* 16:193–201. [https://doi.org/10.1016/s1386-6532\(99\)00083-9](https://doi.org/10.1016/s1386-6532(99)00083-9)
53. Gautheret-Dejean A, Agut H, Nicolas JC, Beaugerie L. 2003. Roseolovirus DNA in the colonic mucosa of HIV-seropositive patients with diarrhea. *Clin Infect Dis* 36:1348–1349. <https://doi.org/10.1086/374873>
54. Wilborn F, Schmidt CA, Lorenz F, Peng R, Gelderblom H, Huhn D, Siebert W. 1995. Human herpesvirus type 7 in blood donors: detection by the polymerase chain reaction. *J Med Virol* 47:65–69. <https://doi.org/10.1002/jmv.1890470113>
55. Yamamoto Y, Morooka M, Hashimoto S, Ihra M, Yoshikawa T. 2014. Analysis of the shedding of three  $\beta$  - herpesviruses in urine and saliva of children with renal disease. *J Med Virol* 86:505–511. <https://doi.org/10.1002/jmv.23782>
56. Di Luca D, Mirandola P, Ravaoli T, Dolcetti R, Frigatti A, Bovenzi P, Sighinolfi L, Monini P, Cassai E. 1995. Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. *J Med Virol* 45:462–468. <https://doi.org/10.1002/jmv.1890450418>
57. Lucht E, Brytting M, Bjerregaard L, Julander I, Linde A. 1998. Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1—infected patients and healthy controls. *Clin Infect Dis* 27:137–141. <https://doi.org/10.1086/514604>
58. Sada E, Yasukawa M, Ito C, Takeda A, Shiosaka T, Tanioka H, Fujita S. 1996. Detection of human herpesvirus 6 and human herpesvirus 7 in the submandibular gland, parotid gland, and lip salivary gland by PCR. *J Clin Microbiol* 34:2320–2321. <https://doi.org/10.1128/jcm.34.9.2320-2321.1996>
59. Fujiwara N, Namba H, Ohuchi R, Isomura H, Uno F, Yoshida M, Nii S, Yamada M. 2000. Monitoring of human herpesvirus - 6 and - 7 genomes in saliva samples of healthy adults by competitive quantitative PCR. *J Med Virol* 61:208–213. [https://doi.org/10.1002/\(sici\)1096-9071\(200006\)61:2<208::aid-jmv6>3.0.co;2-1](https://doi.org/10.1002/(sici)1096-9071(200006)61:2<208::aid-jmv6>3.0.co;2-1)
60. Shanehsazzadeh M, Rad JS-, Pourazar A, Behbahani M. 2014. Epidemiology of herpes human virus 6 and 7 infections in salivary gland neoplasms in Isfahan, Iran. *Med Arch* 68:276–278. <https://doi.org/10.5455/medarh.2014.68.276-278>
61. Black JB, Inoue N, Kite-Powell K, Zaki S, Pellett PE. 1993. Frequent isolation of human herpesvirus 7 from saliva. *Virus Res* 29:91–98. [https://doi.org/10.1016/0168-1702\(93\)90128-a](https://doi.org/10.1016/0168-1702(93)90128-a)
62. Hidaka Y, Liu Y, Yamamoto M, Mori R, Miyazaki C, Kusahara K, Okada K, Ueda K. 1993. Frequent isolation of human herpesvirus 7 from saliva samples. *J Med Virol* 40:343–346. <https://doi.org/10.1002/jmv.1890400416>
63. Franti M, Aubin J-T, Poirel L, Gautheret-Dejean A, Candotti D, Huraux J-M, Agut H. 1998. Definition and distribution analysis of glycoprotein B gene alleles of human herpesvirus 7. *J Virol* 72:8725–8730. <https://doi.org/10.1128/JVI.72.11.8725-8730.1998>
64. Ihira M, Yoshikawa T, Ohashi M, Enomono Y, Akimoto S, Suga S, Saji H, Nishiyama Y, Asano Y. 2003. Variation of human herpesvirus 7 shedding in saliva. *J Infect Dis* 188:1352–1354. <https://doi.org/10.1086/379040>
65. Shannon-Lowe CD, Neuhierl B, Baldwin G, Rickinson AB, Delecluse H-J. 2006. Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. *Proc Natl Acad Sci U S A* 103:7065–7070. <https://doi.org/10.1073/pnas.0510512103>
66. Fraile-Ramos A, Kledal TN, Pelchen-Matthews A, Bowers K, Schwartz TW, Marsh M. 2001. The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling. *Mol Biol Cell* 12:1737–1749. <https://doi.org/10.1091/mbc.12.6.1737>
67. Latchney LR, Fallon MA, Culp DJ, Gelbard HA, Dewhurst S. 2004. Immunohistochemical assessment of fractalkine, inflammatory cells, and human herpesvirus 7 in human salivary glands. *J Histochem Cytochem* 52:671–681. <https://doi.org/10.1177/002215540405200511>
68. Kempf W, Adams V, Wey N, Moos R, Schmid M, Avitabile E, Campadelli-Fiume G. 1997. CD68<sup>+</sup> cells of monocyte/macrophage lineage in the environment of AIDS-associated and classic-sporadic Kaposi sarcoma are singly or doubly infected with human herpesviruses 7 and 6B. *Proc Natl Acad Sci U S A* 94:7600–7605. <https://doi.org/10.1073/pnas.94.14.7600>
69. Griffin BD, Verweij MC, Wiertz EJHJ. 2010. Herpesviruses and immunity: the art of evasion. *Vet Microbiol* 143:89–100. <https://doi.org/10.1016/j.vetmic.2010.02.017>
70. Mirandola P, Secchiero P, Pierpaoli S, Visani G, Zamai L, Vitale M, Capitani S, Zauli G. 2000. Infection of CD34<sup>+</sup> hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). *Blood* 96:126–131. <https://doi.org/10.1182/blood.V96.1.126>

71. Crawford LB. 2023. Hematopoietic stem cells and betaherpesvirus latency. *Front Cell Infect Microbiol* 13:1189805. <https://doi.org/10.3389/fcimb.2023.1189805>
72. Glosson NL, Gonyo P, May NA, Schneider CL, Ristow LC, Wang Q, Hudson AW. 2010. Insight into the mechanism of human herpesvirus 7 U21-mediated diversion of class I MHC molecules to lysosomes. *J Biol Chem* 285:37016–37029. <https://doi.org/10.1074/jbc.M110.125849>
73. Hudson AW, Howley PM, Ploegh HL. 2001. A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes. *J Virol* 75:12347–12358. <https://doi.org/10.1128/JVI.75.24.12347-12358.2001>
74. Hudson AW, Blom D, Howley PM, Ploegh HL. 2003. The ER - lumenal domain of the HHV - 7 immunoevasin U21 directs class I MHC molecules to lysosomes. *Traffic* 4:824–837. <https://doi.org/10.1046/j.1398-9219.2003.0137.x>
75. Dirck AT, Whyte ML, Hudson AW. 2020. HHV-7 U21 exploits Golgi quality control carriers to reroute class I MHC molecules to lysosomes. *Mol Biol Cell* 31:196–208. <https://doi.org/10.1091/mbc.E19-07-0363>
76. Kimpler LA, Glosson NL, Downs D, Gonyo P, May NA, Hudson AW. 2014. Adaptor protein complexes AP-1 and AP-3 are required by the HHV-7 immunoevasin U21 for rerouting of class I MHC molecules to the lysosomal compartment. *PLoS One* 9:e99139. <https://doi.org/10.1371/journal.pone.0099139>
77. Mirandola P, Sponzilli I, Solenghi E, Micheloni C, Rinaldi L, Gobbi G, Vitale M. 2006. Down-regulation of human leukocyte antigen class I and II and B2-microglobulin expression in human herpesvirus-7-infected cells. *J Infect Dis* 193:917–926. <https://doi.org/10.1086/500561>
78. May NA, Glosson NL, Hudson AW. 2010. Human herpesvirus 7 U21 downregulates classical and nonclassical class I major histocompatibility complex molecules from the cell surface. *J Virol* 84:3738–3751. <https://doi.org/10.1128/JVI.01782-09>
79. Schneider CL, Hudson AW. 2011. The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytotoxicity through modulation of MICA and MICB. *PLoS Pathog* 7:e1002362. <https://doi.org/10.1371/journal.ppat.1002362>
80. Atedzoé BN, Menezes J, D'Addario M, Xu J, Ongradi J, Ahmad A. 1999. Modulatory effects of human herpes virus - 7 on cytokine synthesis and cell proliferation in human peripheral blood mononuclear cell cultures. *J Leukoc Biol* 66:822–828. <https://doi.org/10.1002/jlb.66.5.822>
81. Nakano K, Tadagaki K, Isegawa Y, Aye MM, Zou P, Yamanishi K. 2003. Human herpesvirus 7 open reading frame U12 encodes a functional  $\beta$ -chemokine receptor. *J Virol* 77:8108–8115. <https://doi.org/10.1128/JVI.77.14.8108-8115.2003>
82. Tadagaki K, Yamanishi K, Mori Y. 2007. Reciprocal roles of cellular chemokine receptors and human herpesvirus 7-encoded chemokine receptors, U12 and U51. *J Gen Virol* 88:1423–1428. <https://doi.org/10.1099/vir.0.82665-0>
83. Furukawa M, Yasukawa M, Yakushijin Y, Fujita S. 1994. Distinct effects of human herpesvirus 6 and human herpesvirus 7 on surface molecule expression and function of CD4<sup>+</sup> T cells. *J Immunol* 152:5768–5775. <https://doi.org/10.4049/jimmunol.152.12.5768>
84. Secchiero P, Gibellini D, Flamand L, Robuffo I, Marchisio M, Capitani S, Gallo RC, Zauli G. 1997. Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. *J Immunol* 159:3412–3423. <https://doi.org/10.4049/jimmunol.159.7.3412>
85. Sullivan BM, Coscoy L. 2010. The U24 protein from human herpesvirus 6 and 7 affects endocytic recycling. *J Virol* 84:1265–1275. <https://doi.org/10.1128/JVI.01775-09>
86. Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S. 2005. The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion *in vitro*. *J Virol* 79:11914–11924. <https://doi.org/10.1128/JVI.79.18.11914-11924.2005>
87. Greninger AL, Sedlak RH, Jerome KR. 2019. Human herpesviruses 6A, 6B, and 7, p 1814–1825. In *Manual of clinical microbiology*, 12th ed. ASM Press, Washington DC.
88. Clark DA, Freeland JML, Mackie PLK, Jarrett RF, Onions DE. 1993. Prevalence of antibody to human herpesvirus 7 by age. *J Infect Dis* 168:251–252. <https://doi.org/10.1093/infdis/168.1.251>
89. Hall CB, Caserta MT, Schnabel KC, McDermott MP, Lofthus GK, Carnahan JA, Gilbert LM, Dewhurst S. 2006. Characteristics and acquisition of human herpesvirus (HHV)-7 infections in relation to infection with HHV-6. *J Infect Dis* 193:1063–1069. <https://doi.org/10.1086/503434>
90. Bustos D, Biganzoli P, Carricart SE, Ferreyra L, Nates SV, Pavan JV. 2006. Loss of maternally-derived human herpesvirus-7 immunity and natural infection in Argentinian infants. *Int J Infect Dis* 10:354–357. <https://doi.org/10.1016/j.ijid.2005.07.005>
91. Hasan AS, Abdulwahab SA, Lames K. 2023. Prevalence of anti-human herpes virus type 7 IgG positivity rate among children with fever and skin rash in Diyala province, Iraq. *Arch Razi Inst* 78:79–86. <https://doi.org/10.22092/ARI.2022.359149.2381>
92. Krueger GRF, Koch B, Leyssens N, Berneman Z, Rojo J, Horwitz C, Sloots T, Margalith M, Conradie JD, Imai S, Urasinski I, de Bruyère M, Ferrer Argote V, Krueger J. 1998. Comparison of seroprevalences of human herpesvirus-6 and -7 in healthy blood donors from nine countries. *Vox Sanguinis* 75:193–197. <https://doi.org/10.1046/j.1423-0410.1998.7530193.x>
93. Tanaka-Taya K, Kondo T, Mukai T, Miyoshi H, Yamamoto Y, Okada S, Yamanishi K. 1996. Seroepidemiological study of human herpesvirus - 6 and - 7 in children of different ages and detection of these two viruses in throat swabs by polymerase chain reaction. *J Med Virol* 48:88–94. [https://doi.org/10.1002/\(SICI\)1096-9071\(199601\)48:1<88::AID-JMV14>3.0.CO;2-2](https://doi.org/10.1002/(SICI)1096-9071(199601)48:1<88::AID-JMV14>3.0.CO;2-2)
94. Lanphear BP, Hall CB, Black J, Auinger P. 1998. Risk factors for the early acquisition of human herpesvirus 6 and human herpesvirus 7 infections in children. *Pediatr Infect Dis J* 17:792–795. <https://doi.org/10.1097/00006454-199809000-00008>
95. Takahashi Y, Yamada M, Nakamura J, Tsukazaki T, Padilla J, Kitamura T, Yoshida M, Nii S. 1997. Transmission of human herpesvirus 7 through multigenerational families in the same household. *Pediatr Infect Dis J* 16:975–978. <https://doi.org/10.1097/00006454-199710000-00014>
96. Fujisaki H, Tanaka-Taya K, Tanabe H, Hara T, Miyoshi H, Okada S, Yamanishi K. 1998. Detection of human herpesvirus 7 (HHV-7) DNA in breast milk by polymerase chain reaction and prevalence of HHV-7 antibody in breast-fed and bottle-fed children. *J Med Virol* 56:275–279. [https://doi.org/10.1002/\(sici\)1096-9071\(199811\)56:3<275::aid-jmv17>3.0.co;2-d](https://doi.org/10.1002/(sici)1096-9071(199811)56:3<275::aid-jmv17>3.0.co;2-d)
97. Okuno T, Oishi H, Hayashi K, Nonogaki M, Tanaka K, Yamanishi K. 1995. Human herpesviruses 6 and 7 in cervixes of pregnant women. *J Clin Microbiol* 33:1968–1970. <https://doi.org/10.1128/jcm.33.7.1968-1970.1995>
98. Caserta MT, Hall CB, Schnabel K, Lofthus G, McDermott MP. 2007. Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. *J Infect Dis* 196:1296–1303. <https://doi.org/10.1086/522430>
99. Ohashi M, Yoshikawa T, Ihira M, Suzuki K, Suga S, Tada S, Udagawa Y, Sakui H, Iida K, Saito Y, Nisiyama Y, Asano Y. 2002. Reactivation of human herpesvirus 6 and 7 in pregnant women. *J Med Virol* 67:354–358. <https://doi.org/10.1002/jmv.10083>
100. Hall CB, Caserta MT, Schnabel KC, Boettlich C, McDermott MP, Lofthus GK, Carnahan JA, Dewhurst S. 2004. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). *J Pediatr* 145:472–477. <https://doi.org/10.1016/j.jpeds.2004.06.017>
101. Ashshi AM, Klapper PE, Cooper RJ. 2003. Detection of human cytomegalovirus, human herpesvirus type 6 and human herpesvirus type 7 in urine specimens by multiplex PCR. *J Infect* 47:59–64. [https://doi.org/10.1016/S0163-4453\(03\)00057-4](https://doi.org/10.1016/S0163-4453(03)00057-4)
102. Asano Y, Suga S, Yoshikawa T, Yazaki T, Uchikawa T. 1995. Clinical features and viral excretion in an infant with primary human herpesvirus 7 infection. *Pediatrics* 95:187–190.
103. Kozireva S, Nemceva G, Danilane I, Pavlova O, Blomberg J, Murovska M. 2001. Prevalence of blood-borne viral infections (cytomegalovirus, human herpesvirus-6, human herpesvirus-7, human herpesvirus-8, human T-cell lymphotropic virus-I/II, human retrovirus-5) among blood donors in Latvia. *Ann Hematol* 80:669–673. <https://doi.org/10.1007/s002770100359>
104. Hudnall SD, Chen T, Allison P, Tyring SK, Heath A. 2008. Herpesvirus prevalence and viral load in healthy blood donors by quantitative real - time polymerase chain reaction. *Transfusion* 48:1180–1187. <https://doi.org/10.1111/j.1537-2995.2008.01685.x>



105. Zheng Y, Zhao Y, Wang Y, Rao J. 2021. A multiplex real-time PCR quantitation of human herpesvirus-6, 7, 8 viruses: application in blood transfusions. *Viol J* 18:38. <https://doi.org/10.1186/s12985-021-01510-6>
106. Komaroff AL, Pellett PE, Jacobson S. 2020. Human herpesviruses 6A and 6B in brain diseases: association versus causation. *Clin Microbiol Rev* 34:00143–20. <https://doi.org/10.1128/CMR.00143-20>
107. Tanaka K, Kondo T, Torigoe S, Okada S, Mukai T, Yamanishi K. 1994. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). *J Pediatr* 125:1–5. [https://doi.org/10.1016/s0022-3476\(94\)70113-x](https://doi.org/10.1016/s0022-3476(94)70113-x)
108. Suga S, Yoshikawa T, Nagai T, Asano Y. 1997. Clinical features and virological findings in children with primary human herpesvirus 7 infection. *Pediatrics* 99:E4. <https://doi.org/10.1542/peds.99.3.e4>
109. Drago F, Ranieri E, Malaguti F, Battifoglio ML, Losi E, Reborn A. 1997. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin. *Dermatol Basel Switz* 195:374–378. <https://doi.org/10.1159/000254591>
110. Watanabe T, Kawamura T, Jacob SE, Aquilino EA, Orenstein JM, Black JB, Blauvelt A. 2002. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. *J Invest Dermatol* 119:793–797. <https://doi.org/10.1046/j.1523-1747.2002.00200.x>
111. Broccoli F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, Gelmetti C, Lusso P, Rebora AE, Malnati MS. 2005. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. *J Invest Dermatol* 124:1234–1240. <https://doi.org/10.1111/j.0022-202X.2005.23719.x>
112. Watanabe T, Sugaya M, Nakamura K, Tamaki K. 1999. Human herpesvirus 7 and pityriasis rosea. *J Invest Dermatol* 113:288–289. <https://doi.org/10.1046/j.1523-1747.1999.00658.x>
113. Kempf W, Adams V, Kleinhans M, Burg G, Panizzon RG, Campadelli-Fiume G, Nestle FO. 1999. Pityriasis rosea is not associated with human herpesvirus 7. *Arch Dermatol* 135:1070–1072. <https://doi.org/10.1001/archderm.135.9.1070>
114. Yasukawa M, Sada E, MacHino H, Fujita S. 1999. Reactivation of human herpesvirus 6 in pityriasis rosea. *Br J Dermatol* 140:169–170. <https://doi.org/10.1046/j.1365-2133.1999.02630.x>
115. Wong W-R, Tsai C-Y, Shih S-R, Chan H-L. 2001. Association of pityriasis rosea with human herpesvirus-6 and human herpesvirus-7 in Taipei. *J Formos Med Assoc* 100:478–483.
116. Michelerio A, Tchich A, Vassallo C, Brazzelli V. 2023. Atypical exanthem with acral involvement in adult patients associated with human herpesvirus 7 active replication: a case series. *Front Med (Lausanne)* 10:1144856. <https://doi.org/10.3389/fmed.2023.1144856>
117. Vág T, Sonkoly E, Kemény B, Kárpáti S, Horváth A, Ongrádi J. 2003. Studies on the novel association of human herpesvirus-7 with skin diseases. *Orv Hetil* 144:1623–1629.
118. Vág T, Sonkoly E, Kemény B, Kárpáti S, Horváth A, Ongrádi J. 2004. Familiar occurrence of papular-purpuric 'gloves and socks' syndrome with human herpes virus-7 and human parvovirus B19 infection. *J Eur Acad Dermatol Venereol* 18:639–641. <https://doi.org/10.1111/j.1468-3083.2004.00994.x>
119. Hara H, Kobayashi M, Yokoyama A, Tochigi M, Matsunaga A, Shimizu H, Goshima J, Suzuki H. 2005. Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation of human herpesvirus 7. *Dermatology* 211:159–161. <https://doi.org/10.1159/000086449>
120. Mitani N, Aihara M, Yamakawa Y, Yamada M, Itoh N, Mizuki N, Ikezawa Z. 2005. Drug-induced hypersensitivity syndrome due to cyanamide associated with multiple reactivation of human herpesviruses. *J Med Virol* 75:430–434. <https://doi.org/10.1002/jmv.20295>
121. Yagami A, Yoshikawa T, Asano Y, Koie S, Shiohara T, Matsunaga K. 2006. Drug-induced hypersensitivity syndrome due to mexiletine hydrochloride associated with reactivation of human herpesvirus 7. *Dermatology* 213:341–344. <https://doi.org/10.1159/000096200>
122. Draz N, Datta S, Webster DP, Cropley I. 2013. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculous drugs and associated with human herpes virus-7 (HHV-7). *BMJ Case Rep* 2013:bcr2013010348. <https://doi.org/10.1136/bcr-2013-010348>
123. Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. 2006. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. *Br J Dermatol* 155:344–349. <https://doi.org/10.1111/j.1365-2133.2006.07332.x>
124. Shen MH, Liu MT, Chung WH, Lu CW. 2020. Toxic epidermal necrolysis induced by human herpesvirus 7 treated with a tumor necrosis factor- $\alpha$  inhibitor. *J Dermatol* 47:1179–1181. <https://doi.org/10.1111/1346-8138.15493>
125. Nahidi Y, Tayyebi Meibodi N, Ghazvini K, Esmaily H, Esmaealzadeh M. 2017. Association of classic lichen planus with human herpesvirus - 7 infection. *Int J Dermatol* 56:49–53. <https://doi.org/10.1111/ijd.13416>
126. OFlatharta C, Flint SR, Toner M, Butler D, Mabruk MJEMF. 2003. Investigation into a possible association between oral lichen planus, the human herpesviruses, and the human papillomaviruses. *Mol Diagn* 7:73–83. <https://doi.org/10.1007/BF03260023>
127. Azzam OA, Fawzi MMT, Abu Zeid OM, El Rifaii AA, Ahmed MES, Rashed L. 2013. Expression of toll-like receptor 9 and human herpes virus 7 in lichen planus. *J Egypt Women's Dermatol Soc* 10:32–36. <https://doi.org/10.1097/01.EWX.0000421879.72438.26>
128. Torigoe S, Kumamoto T, Koide W, Taya K, Yamanishi K. 1995. Clinical manifestations associated with human herpesvirus 7 infection. *Arch Dis Child* 72:518–519. <https://doi.org/10.1136/adc.72.6.518>
129. Torigoe S, Koide W, Yamada M, Miyashiro E, Tanaka-Taya K, Yamanishi K. 1996. Human herpesvirus 7 infection associated with central nervous system manifestations. *J Pediatr* 129:301–305. [https://doi.org/10.1016/s0022-3476\(96\)70259-7](https://doi.org/10.1016/s0022-3476(96)70259-7)
130. Drago F, Broccoli F, Ciccarese G, Rebora A, Parodi A. 2015. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. *Dermatology* 230:23–26. <https://doi.org/10.1159/000368352>
131. Ongrádi J, Becker K, Horváth A, Hidvégi E, Mezey I. 2000. Simultaneous infection by human herpesvirus 7 and human parvovirus B19 in papular-purpuric gloves-and-socks syndrome. *Arch Dermatol* 136:672–673. <https://doi.org/10.1001/archderm.136.5.672>
132. Keung Yeung C, Peiris M, Ma SY, Chan HHL, Hon C. 2003. Aetiology in sixteen cases of toxic epidermal necrolysis and Stevens-Johnson syndrome admitted within eight months in a teaching hospital. *Acta Dermato-Venereologica* 83:179–182. <https://doi.org/10.1080/00015550310007166>
133. Aihara M, Mitani N, Kakemizu N, Yamakawa Y, Inomata N, Ito N, Komatsu H, Aihara Y, Ikezawa Z. 2004. Human herpesvirus infection in drug-induced hypersensitivity syndrome, toxic epidermal necrolysis and Stevens-Johnson syndrome. *Allergol Int* 53:23–29. <https://doi.org/10.1046/j.1440-1592.2003.00309.x>
134. Drago F, Paolino S, Rebora A, Broccoli F, Drago F, Cardo P, Parodi A. 2012. The challenge of diagnosing atypical exanthems: a clinico-laboratory study. *J Am Acad Dermatol* 67:1282–1288. <https://doi.org/10.1016/j.jaad.2012.04.014>
135. Ashforth GM, Youssef S, Bhagavathi V, Wassef C, Miller JH. 2023. What's old is new: valacyclovir for the treatment of pityriasis rosea, a retrospective case series. *JAAD Case Rep* 37:98–102. <https://doi.org/10.1016/j.jcdr.2023.05.015>
136. Chang H-C, Sung C-W, Lin M-H. 2019. The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis. *J Dermatol Treat* 30:288–293. <https://doi.org/10.1080/09546634.2018.1508820>
137. Tzur L, Yang F-S, Deverapalli S. 2022. The use of antivirals in severe or recalcitrant cases of pityriasis rosea: a case series. *JAAD Case Rep* 28:100–103. <https://doi.org/10.1016/j.jcdr.2022.05.032>
138. Epstein LG, Shinnar S, Hesdorffer DC, Nordli DR, Hamidullah A, Benn EKT, Pellock JM, Frank LM, Lewis DV, Moshe SL, Shinnar RC, Sun S, FEBSTAT study team. 2012. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. *Epilepsia* 53:1481–1488. <https://doi.org/10.1111/j.1528-1167.2012.03542.x>
139. Caserta MT, Hall CB, Schnabel K, Long CE, D'Heron N. 1998. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. *J Pediatr* 133:386–389. [https://doi.org/10.1016/s0022-3476\(98\)70275-6](https://doi.org/10.1016/s0022-3476(98)70275-6)
140. Foidelli T, Rossi V, Paolucci S, Rovida F, Novazzi F, Orsini A, Brambilla I, Marsaglia GL, Baldanti F, Savasta S. 2022. Human herpes virus 7-related encephalopathy in children. *Acta Biomed* 92:e2021415. <https://doi.org/10.23750/abm.v92i54.12664>
141. Pohl-Koppe A, Blay M, Jäger G, Weiss M. 2001. Human herpes virus type 7 DNA in the cerebrospinal fluid of children with central nervous system diseases. *Eur J Pediatr* 160:351–358. <https://doi.org/10.1007/s004310100732>

142. Sugaya N, Yoshikawa T, Miura M, Ishizuka T, Kawakami C, Asano Y. 2002. Influenza encephalopathy associated with infection with human herpesvirus 6 and/or human herpesvirus 7. *Clin Infect Dis* 34:461–466. <https://doi.org/10.1086/338468>
143. Christou E, Mastrogianni S, Bourousis E, Bachou T, Tsirikas T, Mouskou S, Voudris K, Delis D. 2022. A case of seronegative autoimmune encephalitis associated with human herpesvirus-7 (HHV-7). *J Med Virol* 94:795–798. <https://doi.org/10.1002/jmv.27411>
144. Li S, Wang M, Li H, Wang J, Zhang Q, Zhou D, Li J. 2022. Case report: overlapping syndrome of anti-NMDAR encephalitis and MOG inflammatory demyelinating disease in a patient with human herpesviruses 7 infection. *Front Immunol* 13:799454. <https://doi.org/10.3389/fimmu.2022.799454>
145. Ward KN, Andrews NJ, Verity CM, Miller E, Ross EM. 2005. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. *Arch Dis Child* 90:619–623. <https://doi.org/10.1136/adc.2004.062216>
146. van den Berg JSP, van Zeijl JH, Rotteveel JJ, Melchers WJG, Gabreëls FJM, Galama JMD. 1999. Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations. *Neurology* 52:1077–1077. <https://doi.org/10.1212/WNL.52.5.1077>
147. Schwartz KL, Richardson SE, Ward KN, Donaldson C, MacGregor D, Banwell B, Mahant S, Bitnun A. 2014. Delayed primary HHV-7 infection and neurologic disease. *Pediatrics* 133:e1541–e1547. <https://doi.org/10.1542/peds.2013-3344>
148. Corral Í, Sainz de la Maza S, Rodríguez M, Kawiorski M-M, López-Martínez M-J, Galán J-C. 2018. Molecular detection of human herpesvirus 7 DNA in cerebrospinal fluid from adult patients with neurological disorders. *J Neurovirol* 24:333–338. <https://doi.org/10.1007/s13365-018-0618-4>
149. Ward KN, Kalima P, MacLeod KM, Riordan T. 2002. Neuroinvasion during delayed primary HHV-7 infection in an immunocompetent adult with encephalitis and flaccid paralysis. *J Med Virol* 67:538–541. <https://doi.org/10.1002/jmv.10135>
150. Aburakawa Y, Katayama T, Saito T, Sawada J, Suzutani T, Aizawa H, Hasebe N. 2017. Limbic encephalitis associated with human herpesvirus-7 (HHV-7) in an immunocompetent adult: the first reported case in Japan. *Intern Med* 56:1919–1923. <https://doi.org/10.2169/internalmedicine.56.8185>
151. Parra M, Alcalá A, Amoros C, Baeza A, Galiana A, Tarragó D, García-Quesada MA, Sánchez-Hellín V. 2017. Encephalitis associated with human herpesvirus-7 infection in an immunocompetent adult. *Virol J* 14:97. <https://doi.org/10.1186/s12985-017-0764-y>
152. Riva N, Franconi I, Meschiari M, Franceschini E, Puzzolante C, Cuomo G, Bianchi A, Cavalleri F, Genovese M, Mussini C. 2017. Acute human herpes virus 7 (HHV-7) encephalitis in an immunocompetent adult patient: a case report and review of literature. *Infection* 45:385–388. <https://doi.org/10.1007/s15010-017-1014-3>
153. Chan PKS, Chik KW, To KF, Li CK, Shing MMK, Ng KC, Yuen PMP, Cheng AF. 2002. Case report: human herpesvirus 7 associated fatal encephalitis in a peripheral blood stem cell transplant recipient. *J Med Virol* 66:493–496. <https://doi.org/10.1002/jmv.2171>
154. Holden SR, Vas AL. 2007. Severe encephalitis in a haematopoietic stem cell transplant recipient caused by reactivation of human herpesvirus 6 and 7. *J Clin Virol* 40:245–247. <https://doi.org/10.1016/j.jcv.2007.08.011>
155. Fay AJ, Noetzel MJ, Mar SS. 2015. Pediatric hemorrhagic brainstem encephalitis associated with HHV-7 infection. *Pediatr Neurol* 53:523–526. <https://doi.org/10.1016/j.pediatrneurol.2015.06.016>
156. Grose C. 2022. Metagenomic sequencing of cerebrospinal fluid from children with meningitis. *EBioMedicine* 84:104287. <https://doi.org/10.1016/j.ebiom.2022.104287>
157. Wada K, Mizoguchi S, Ito Y, Kawada JI, Yamauchi Y, Morishima T, Nishiyama Y, Kimura H. 2009. Multiplex real-time PCR for the simultaneous detection of herpes simplex virus, human herpesvirus 6, and human herpesvirus 7. *Microbiol Immunol* 53:22–29. <https://doi.org/10.1111/j.1348-0421.2008.00090.x>
158. Ikeda-Murakami K, Ikeda T, Tani N, Aoki Y, Ishikawa T. 2022. Sudden child death with acute encephalitis due to human herpesvirus 7: a case report and review of the literature. *Forensic Sci Int Rep* 5:100249. <https://doi.org/10.1016/j.fsir.2021.100249>
159. Chapenko S, Roga S, Skuja S, Rasa S, Cistjakovs M, Svirskis S, Zaserska Z, Groma V, Murovska M. 2016. Detection frequency of human herpesviruses-6A, -6B, and -7 genomic sequences in central nervous system DNA samples from post-mortem individuals with unspecified encephalopathy. *J Neurovirol* 22:488–497. <https://doi.org/10.1007/s13365-015-0417-0>
160. Yoshikawa T, Yoshida J, Hamaguchi M, Kubota T, Akimoto S, Ihira M, Nishiyama Y, Asano Y. 2003. Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation. *J Med Virol* 70:440–443. <https://doi.org/10.1002/jmv.10414>
161. Marcelo Miranda C, Juan Pablo Torres T, Carmen Larrañaga L, Guillermo Acuña L. 2011. Meningomyelitis associated with infection by human herpes virus 7: report of two cases. *Rev Med Chil* 139:1588–1591. <https://doi.org/10.4067/S0034-98872011001200008>
162. Fares R, Matar M. 2023. Human herpesvirus-7 meningitis in an immunocompetent adult patient: a case report. *Future Sci OA* 9:F50876. <https://doi.org/10.2144/fsoa-2023-0021>
163. Escobar-Villalba A, Sainz de la Maza S, Pérez Torre P, Galán JC, Rodríguez-Domínguez M, Monreal Laguillo E, Martínez Ulloa PL, Buisán Catevilla J, Corral I. 2016. Acute myelitis by human herpes virus 7 in an HIV-infected patient. *J Clin Virol* 77:63–65. <https://doi.org/10.1016/j.jcv.2016.02.001>
164. Ward KN, White RP, Mackinnon S, Hanna M. 2002. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. *Bone Marrow Transplant* 30:983–985. <https://doi.org/10.1038/sj.bmt.1703774>
165. Mihara T, Mutoh T, Yoshikawa T, Yano S, Asano Y, Yamamoto H. 2005. Postinfectious myeloradiculoneuropathy with cranial nerve involvements associated with human herpesvirus 7 infection. *Arch Neurol* 62:1755–1757. <https://doi.org/10.1001/archneur.62.11.1755>
166. Li J-M, Huang C, Yan B, Wang W, Zhou Q, Sander JW, Zhou D. 2014. HHV-7 in adults with drug-resistant epilepsy: a pathological role in hippocampal sclerosis? *J Clin Virol* 61:387–392. <https://doi.org/10.1016/j.jcv.2014.08.017>
167. Ginanneschi F, Donati D, Moschetti D, Dominici F, Cermelli C, Rossi A. 2007. Encephaloradiculomyelitis associated to HHV-7 and CMV co-infection in immunocompetent host. *Clin Neurol Neurosurg* 109:272–276. <https://doi.org/10.1016/j.clineuro.2006.04.002>
168. Rangel MA, Moreira D, Vila Real M, Santos F. 2017. Meningoradiculopathy associated with human herpesvirus 7 - A virus with potential to cause severe neurologic disease with sequelae. *Pediatr Infect Dis J* 36:427–429. <https://doi.org/10.1097/INF.0000000000001459>
169. Chan PK, Ng HK, Cheung JL, Ng KC, Cheng AF. 2000. Prevalence and distribution of human herpesvirus 7 in normal brain. *J Med Virol* 62:345–348. [https://doi.org/10.1002/1096-9071\(200011\)62:3<345::aid-jmv6>3.0.co;2-#](https://doi.org/10.1002/1096-9071(200011)62:3<345::aid-jmv6>3.0.co;2-#)
170. Hacoen Y, Niotakis G, Aujla A, Siddiqui A, McCormick D, Bassi S, Clarke A, Lim M. 2011. Acute life threatening cerebellitis presenting with no apparent cerebellar signs. *Clin Neurol Neurosurg* 113:928–930. <https://doi.org/10.1016/j.clineuro.2011.06.014>
171. Kittaka S, Hasegawa S, Ito Y, Ohbuchi N, Suzuki E, Kawano S, Aoki Y, Nakatsuka K, Kudo K, Wakiguchi H, Kajimoto M, Matsushige T, Ichiyama T. 2014. Serum levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in human herpesvirus-6-infected infants with or without febrile seizures. *J Infect Chemother* 20:716–721. <https://doi.org/10.1016/j.jiac.2014.07.017>
172. Khandpur S, Ahuja R. 2022. Drug-induced vs. viral maculopapular exanthem—resolving the dilemma. *Dermatopathology (Basel)* 9:164–171. <https://doi.org/10.3390/dermatopathology9020021>
173. Engelmann I, Ogiez J, Ogiez L, Alidjinou EK, Lazrek M, Dewilde A, Hober D. 2018. Relapsing pityriasis rosea with HHV-7 reactivation in an 11-year-old girl. *Pediatrics* 141:e20173179. <https://doi.org/10.1542/peds.2017-3179>
174. Karabulut AA, Koçak M, Yilmaz N, Eksioğlu M. 2002. Detection of human herpesvirus 7 in pityriasis rosea by nested PCR. *Int J Dermatology* 41:563–567. <https://doi.org/10.1046/j.1365-4362.2002.01584.x>
175. Drago F, Malaguti F, Ranieri E, Losi E, Rebora A. 2002. Human herpes virus - like particles in pityriasis rosea lesions: an electron microscopy study. *J Cutan Pathol* 29:359–361. <https://doi.org/10.1034/j.1600-0560.2002.290606.x>
176. Santpere G, Telford M, Andrés-Benito P, Navarro A, Ferrer I. 2020. The presence of human herpesvirus 6 in the brain in health and disease. *Biomolecules* 10:1520. <https://doi.org/10.3390/biom10111520>
177. Kidd IM, Clark DA, Sabin CA, Andrew D, Hassan-Walker AF, Sweny P, Griffiths PD, Emery VC. 2000. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and

- increased rejection. *Transplantation* 69:2400–2404. <https://doi.org/10.1097/00007890-200006150-00032>
178. Griffiths PD, Ait-Khaled M, Bearcroft CP, Clark DA, Quaglia A, Davies SE, Burroughs AK, Rolles K, Kidd IM, Knight SN, Noibi SM, Cope AV, Phillips AN, Emery VC. 1999. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. *J Med Virol* 59:496–501. [https://doi.org/10.1002/\(sici\)1096-9071\(199912\)59:4<496::aid-jmv12>3.0.co;2-u](https://doi.org/10.1002/(sici)1096-9071(199912)59:4<496::aid-jmv12>3.0.co;2-u)
  179. Tong CY, Bakran A, Williams H, Cheung CY, Peiris JS. 2000. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. *Transplantation* 70:213–216.
  180. Osman HK, Peiris JS, Taylor CE, Warwicker P, Jarrett RF, Madeley CR. 1996. "Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? *J Med Virol* 48:295–301. [https://doi.org/10.1002/\(SICI\)1096-9071\(199604\)48:4<295::AID-JMV1>3.0.CO;2-2](https://doi.org/10.1002/(SICI)1096-9071(199604)48:4<295::AID-JMV1>3.0.CO;2-2)
  181. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV. 2001. Human  $\beta$ -herpesvirus interactions in solid organ transplant recipients. *J Infect Dis* 183:179–184. <https://doi.org/10.1086/317929>
  182. Ross DJ, Chan RC, Kubak B, Ardehali A, Laks H, Nichols WS. 2001. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpes virus-7 infection after lung transplantation. *J Heart Lung Transplant* 20:171. [https://doi.org/10.1016/s1053-2498\(00\)00338-7](https://doi.org/10.1016/s1053-2498(00)00338-7)
  183. Khanani M, Al-Ahmari A, Tellier R, Allen U, Richardson S, Doyle JJ, Gassas A. 2007. Human herpesvirus 7 in pediatric hematopoietic stem cell transplantation. *Pediatr Blood Cancer* 48:567–570. <https://doi.org/10.1002/xbc.20829>
  184. Berneman ZN, Gallo RC, Ablashi DV, Frenkel N, Katsafanas G, Kramarsky B, Brus I. 1992. Human herpesvirus 7 (HHV-7) strain J1: independent confirmation of HHV-7. *J Infect Dis* 166:690–691. <https://doi.org/10.1093/infdis/166.3.690>
  185. Chiu HH, Lee CY, Lee PI, Lin KH, Huang LM. 1998. Mononucleosis syndrome and coincidental human herpesvirus-7 and Epstein-Barr virus infection. *Arch Dis Child* 78:479–480. <https://doi.org/10.1136/adc.78.5.479>
  186. Kawa-Ha K, Tanaka K, Inoue M, Sakata N, Okada S, Kurata T, Mukai T, Yamanishi K. 1993. Isolation of human herpesvirus 7 from a child with symptoms mimicking chronic Epstein - Barr virus infection. *Br J Haematol* 84:545–548. <https://doi.org/10.1111/j.1365-2141.1993.tb03118.x>
  187. Sairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T. 1995. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. *Intervirology* 38:269–273. <https://doi.org/10.1159/000150450>
  188. Costa C, Bergallo M, Delsedime L, Solidoro P, Donadio P, Cavallo R. 2009. Acute respiratory distress syndrome associated with HHV-7 infection in an immunocompetent patient: a case report. *New Microbiol* 32:315–316.
  189. Yamamoto K, Yoshikawa T, Okamoto S, Yamaki K, Shimokata K, Nishiyama Y. 2005. HHV - 6 and 7 DNA loads in lung tissues collected from patients with interstitial pneumonia. *J Med Virol* 75:70–75. <https://doi.org/10.1002/jmv.20239>
  190. Hashida T, Komura E, Yoshida M, Otsuka T, Hibi S, Imashuku S, Imashuku S, Ishizaki T, Yamada A, Suga S. 1995. Hepatitis in association with human herpesvirus-7 infection. *Pediatrics* 96:783–785. <https://doi.org/10.1542/peds.96.4.783>
  191. Chanas A, Tomik A, Werner B, Department of Paediatric Cardiology and General Paediatrics, Medical University of Warsaw, Warsaw, Poland. 2021. Recurrent HHV-7 myocarditis in a 16-year-old boy. *Pediatr Med Rodz* 17:67–71. <https://doi.org/10.15557/PiMR.2021.0011>
  192. Ozdemir R, Kucuk M, Dibeklioglu SE. 2018. Report of a myocarditis outbreak among pediatric patients: human herpesvirus 7 as a causative agent? *J Trop Pediatr* 64:468–471. <https://doi.org/10.1093/tropej/fmx093>
  193. Krumina A, Chapenko S, Kenina V, Mihailova M, Logina I, Rasa S, Gintere S, Viksna L, Svirskis S, Murovska M. 2019. The role of HHV-6 and HHV-7 infections in the development of fibromyalgia. *J Neurovirol* 25:194–207. <https://doi.org/10.1007/s13365-018-0703-8>
  194. Yoshikawa T, Ihira M, Taguchi H, Yoshida S, Asano Y. 2005. Analysis of shedding of  $\beta$  - herpesviruses in saliva from patients with connective tissue diseases. *J Infect Dis* 192:1530–1536. <https://doi.org/10.1086/496890>
  195. Thomasini RL, Bonon SH, Durante P, Costa SCB. 2012. Correlation of cytomegalovirus and human herpesvirus 7 with CD3<sup>+</sup> and CD3<sup>+</sup> CD4<sup>+</sup> cells in chronic periodontitis patients. *J Periodontol Res* 47:114–120. <https://doi.org/10.1111/j.1600-0765.2011.01413.x>
  196. Wang B, Saito Y, Nishimura M, Ren Z, Tjan LH, Refaat A, Iida-Norita R, Tsukamoto R, Komatsu M, Itoh T, Matozaki T, Mori Y. 2020. An animal model that mimics human herpesvirus 6B pathogenesis. *J Virol* 94:e01851-19. <https://doi.org/10.1128/JVI.01851-19>
  197. Patel SJ, Zhao G, Penna VR, Park E, Lauron EJ, Harvey IB, Beatty WL, Plougastel-Douglas B, Poursine-Laurent J, Fremont DH, Wang D, Yokoyama WM. 2017. A murine herpesvirus closely related to ubiquitous human herpesviruses causes T-cell depletion. *J Virol* 91:e02463-16. <https://doi.org/10.1128/JVI.02463-16>
  198. Fisher MA, Lloyd ML. 2020. A review of murine cytomegalovirus as a model for human cytomegalovirus disease—do mice lie? *Int J Mol Sci* 22:214. <https://doi.org/10.3390/ijms22010214>
  199. Staheli JP, Dyen MR, Deutsch GH, Basom RS, Fitzgibbon MP, Lewis P, Barcy S. 2016. Complete unique genome sequence, expression profile, and salivary gland tissue tropism of the herpesvirus 7 homolog in pigtailed macaques. *J Virol* 90:6657–6674. <https://doi.org/10.1128/JVI.00651-16>
  200. Van Cleemput J, Koyuncu OO, Laval K, Engel EA, Enquist LW. 2021. CRISPR/Cas9-constructed pseudorabies virus mutants reveal the importance of UL13 in alphaherpesvirus escape from genome silencing. *J Virol* 95:10–1128. <https://doi.org/10.1128/JVI.02286-20>
  201. Van Cleemput J, Poelaert KCK, Laval K, Maes R, Hussey GS, Van den Broeck W, Nauwynck HJ. 2017. Access to a main alphaherpesvirus receptor, located basolaterally in the respiratory epithelium, is masked by intercellular junctions. *Sci Rep* 7:16656. <https://doi.org/10.1038/s41598-017-16804-5>